ART-TG accelerates the development of cell and gene therapies by providing pharmaceutical expertise on gene therapy products and technologies including preclinical studies, quality controls, development of production processes and industrial transfer.
LENTIVIRAL VECTOR PRODUCTION
Standardized upstream and downstream production processes for preclinical lots, from small scale to large scale. Process innovation and automation to maximize capacity, yields and reduce costs. Industrial transfer towards cGMP.
Molecular analysis of genome-modified cells including lentiviral vector copy number determina-tion, lentiviral vector genomic insertion site analyses using standardized materials.
Automation of processes in new devices, use of artificial intelligence in bioproduction to maximize product quality, production capacity, yields and to reduce costs.
New gene therapies targeting immune or hematopoietic cells (B or T lymphocytes, CD34+ cells) based on technologies for gene addition or CRISPR/Cas gene editing. Preclinical studies, characterization, potency and safety assays.